AZN Reports Strong Q3 2025 Core EPS Growth, Exceeding Estimates

AstraZeneca (AZN.US) reported robust financial results for Q3 2025, with Core Earnings Per Share (EPS) reaching $2.38, surpassing analyst estimates of $1.14. Total Revenue for the quarter stood at $15.191 billion, marking a 12% increase from Q3 2024. This performance was driven by strong growth across all therapy areas, positioning the company favorably for its 2030 ambition.

Therapy Area Performance

The company demonstrated significant growth across its key therapy areas in Q3 2025. Oncology Product Revenue rose by 19% (18% at constant exchange rates) to $6.636 billion, while Respiratory & Immunology (R&I) Product Revenue increased by 15% (14% at constant exchange rates) to $2.259 billion. Rare Disease Product Revenue also saw a healthy increase of 12% (11% at constant exchange rates) to $2.416 billion, highlighting broad-based strength.

Pipeline and Strategic Developments

AstraZeneca achieved an unprecedented 16 positive Phase III readouts and 31 approvals in major regions during the first nine months of 2025. This includes high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer. The company is also strengthening its US operations with a historic agreement with the US government to lower medicine costs for American patients and a new $4.5 billion manufacturing facility in Virginia.

Management Outlook

CEO Pascal Soriot affirmed the strong underlying momentum and expressed confidence in sustaining growth through 2026, remaining on track to achieve the 2030 ambition. AstraZeneca reiterates its full-year 2025 guidance, expecting Total Revenue to increase by a high single-digit percentage and Core EPS to increase by a low double-digit percentage at constant exchange rates.